Welcome to our dedicated page for Biomea Fusion news (Ticker: BMEA), a resource for investors and traders seeking the latest updates and insights on Biomea Fusion stock.
Biomea Fusion, Inc. (BMEA) is a clinical-stage biopharmaceutical company pioneering oral covalent small molecule therapies for genetically defined cancers and metabolic disorders. This page provides investors and researchers with timely updates on the company's scientific advancements, clinical trial progress, and strategic initiatives.
Access authoritative updates on Biomea Fusion's pipeline developments, including its lead candidate icovamenib (menin inhibitor) and explore how its proprietary FUSION™ System drives innovation in precision oncology and diabetes research. Stay informed about material events such as clinical data readouts, regulatory milestones, and partnership announcements.
Key updates include progress in Phase I/II studies for oncology targets, metabolic disorder therapeutic breakthroughs, and peer-reviewed research publications. All content is curated to meet investor needs for decision-critical information while maintaining compliance with financial disclosure standards.
Bookmark this page for direct access to Biomea Fusion's latest press releases, SEC filings, and objective third-party analyses. Check regularly for developments in covalent inhibitor research and the company's contributions to advancing targeted therapies for complex diseases and metabolic conditions.
Biomea Fusion (NASDAQ: BMEA) has presented groundbreaking clinical data for icovamenib, their investigational covalent menin inhibitor, at the ATTD 2025 Conference. The drug demonstrated significant improvement in pancreatic beta-cell function in patients with severe insulin-deficient diabetes.
Key findings include:
- 53% mean increase in C-peptide levels 3 months after the last dose
- Strong correlation between C-peptide increase and HbA1c reduction (r=-0.73, p<0.0001)
- Statistically significant placebo-adjusted mean reduction in HbA1c of 1.47% at Week 26 (p=0.022)
- Enhanced responsiveness to GLP-1-based medicines in preclinical studies
The results suggest icovamenib's potential as a first-in-class, disease-modifying therapy by targeting beta-cell restoration and enhancing insulin secretion, with benefits persisting beyond the treatment period. The treatment shows particular promise for severe insulin-deficient diabetes, affecting over 100 million people worldwide.
Biomea Fusion (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, has announced an inducement grant under Nasdaq Listing Rule 5635(c)(4). The compensation committee approved non-qualified stock options for one new employee to purchase 25,000 shares of common stock on March 3, 2025. The stock options will vest quarterly over four years, with 1/16 of shares vesting each quarter, contingent on continued employment. This grant was made under Biomea's 2023 Inducement Equity Plan, which was adopted by the board on November 17, 2023, as an inducement for employment.
Biomea Fusion (BMEA) will present new clinical data for its diabetes drug icovamenib at the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2025) in Amsterdam, March 19-22, 2025.
The company will deliver two oral presentations, one poster presentation, and chair a symposium, featuring new findings from the COVALENT-111 study's Expansion Phase. The data demonstrates icovamenib's potential in enhancing beta cell function and providing sustained glycemic control in type 2 diabetes patients, with effects lasting 14 weeks post-treatment.
Previous results showed significant HbA1c reductions after 12 weeks of treatment in patients with insulin-deficient type 2 diabetes uncontrolled on standard therapies. The presentations will include new c-peptide data and preclinical results combining icovamenib with GLP-1 receptor agonists, positioning it as a potential first-in-class, disease-modifying therapy for severe insulin-deficient type 2 diabetes, which affects over 100 million adults worldwide.
Biomea Fusion (NASDAQ: BMEA) announced its strategic transformation into a diabetes and obesity medicines company, focusing on icovamenib development for metabolic disorders. The company will conclude its oncology studies and explore partnerships for these assets.
Key clinical trial results for icovamenib showed:
- 1.5% mean reduction in HbA1c in severe insulin deficient patients vs placebo
- 1.0% HbA1c reduction in patients on GLP-1-based therapies
- 100% response rate in severely insulin deficient patients at 100mg dose
- Durable effects lasting 14 weeks post-treatment
- Favorable safety profile with no adverse-event related discontinuations
The company plans two clinical trials:
- Phase 2/3 adaptive trial for insulin deficient type 2 diabetes patients
- Phase 2b trial combining icovamenib with GLP-1-based therapy
Biomea Fusion (NASDAQ: BMEA) announced new preclinical data for the combination of icovamenib with semaglutide. The study demonstrated significant improvements compared to semaglutide alone, including an additional 11.5% body weight reduction and a 43% increase in lean muscle mass.
The combination therapy showed approximately doubled C-peptide production per unit of glucose compared to semaglutide alone, resulting in a 60% improved reduction of fasting blood glucose. Previous ex vivo human islet experiments showed icovamenib enhanced GLP-1-based therapies' activity, increasing insulin secretion.
Additionally, topline data from the COVALENT-111 study revealed that 12 weeks of daily icovamenib in patients uncontrolled on GLP-1-based therapy (n=10) achieved an HbA1c reduction of 0.84% at week 26. Further data will be presented at the upcoming J.P. Morgan Conference in January 2025.
Biomea Fusion (Nasdaq: BMEA), a clinical-stage biopharmaceutical company focused on developing oral covalent small molecules for diabetes, obesity, and genetically defined cancers, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference.
Thomas Butler, CEO and Board Chairman, will deliver a presentation on Wednesday, January 15, 2025, at 1:30 PM PT / 4:30 PM ET. The company's management team will also conduct one-on-one meetings throughout the conference, which runs from January 13 to January 16.
Interested parties can access a live audio webcast of the presentation through the company's investor relations website at investors.biomeafusion.com/news-events/events, with a replay available after the live presentation.
Biomea Fusion (BMEA) announced positive topline results from its Phase II COVALENT-111 study evaluating icovamenib in type 2 diabetes patients. The study met its primary endpoint, showing statistically significant HbA1c reductions across all major categories. The most significant results were observed in insulin-deficient patients, with a placebo-adjusted mean reduction of 1.47% in HbA1c at Week 26 in the severe insulin-deficient diabetes (SIDD) group.
The study enrolled 225 patients, with 168 completing the per-protocol analysis. The optimal dosing was identified as 100mg once daily for 12 weeks, showing a mean HbA1c reduction of 0.5%. Notably, the drug demonstrated efficacy in patients who failed GLP-1 based therapy, achieving an HbA1c reduction of 0.84%. The treatment was well-tolerated with no serious adverse events or discontinuations due to adverse events.
Biomea Fusion (BMEA) has announced a conference call and webcast scheduled for Tuesday, December 17, 2024, at 8:00 am EST to present topline results from COVALENT-111, their Phase II trial of icovamenib in patients with type 2 diabetes. The company, which focuses on developing oral covalent small molecules for diabetes, obesity, and genetically defined cancers, will make the webcast available to registered attendees through their investor relations website, with a replay available afterward.
Biomea Fusion (NASDAQ: BMEA) presented significant preclinical findings for icovamenib, their investigational covalent menin inhibitor, at the 22nd WCIRDC. The research demonstrated that icovamenib enhanced beta cell function and improved responsiveness to GLP-1-based therapies in human islets. Key findings showed increased expression of GLP-1 receptors and intracellular insulin, with synergistic effects when combined with therapies like semaglutide and tirzepatide.
The data suggests that icovamenib's ability to increase beta cell mass could potentially allow for lower doses of GLP-1-based therapies while maintaining glycemic targets, potentially reducing side effects. Clinical case studies indicated that short-term icovamenib treatment was well-tolerated with no significant adverse events or hypoglycemia reported.
Biomea Fusion (BMEA) announced preliminary data from its Phase I COVALENT-103 study of BMF-500, a covalent FLT3 inhibitor for relapsed or refractory acute leukemia. The study enrolled 20 patients, including 13 with confirmed FLT3-mutations, who had previously failed gilteritinib treatment.
Key findings include: no dose-limiting toxicities across all dose levels, favorable safety profile, and demonstrated FLT3 inhibition with bone marrow penetration. Clinical activity was observed with one complete response with incomplete hematologic recovery (CRi) at 100mg twice daily dosing, and bone marrow blast reductions in 5 of 6 evaluable FLT3 mutated patients.
The highlighted case study showed a CRi in a 61-year-old patient with R/R AML who had failed four prior treatment regimens.
FAQ
What is the current stock price of Biomea Fusion (BMEA)?
What is the market cap of Biomea Fusion (BMEA)?
